Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Thomas Giever"'
Autor:
Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, Guillaume Cartron, Michael Hallek, Barbara Eichhorst, Mark F. Kozloff, Thomas Giever, Gerard Lozanski, Yanwen Jiang, Huang Huang, Daniela Soriano Pignataro, William Schary, Kathryn Humphrey, Mehrdad Mobasher, Gilles Salles
Publikováno v:
Haematologica, Vol 106, Iss 11 (2020)
Venetoclax (Ven), an orally administered, potent BCL-2 inhibitor, has demonstrated efficacy in chronic lymphocytic leukemia (CLL) in combination with rituximab (R) or obinutuzumab (G). Our aim was to investigate the addition of bendamustine (B) to th
Externí odkaz:
https://doaj.org/article/1a1f8f69ec2f440c9474f9d204dd342e
Publikováno v:
MedEdPORTAL, Vol 10 (2014)
Abstract Introduction Fellowship Programs must soon comply with the ACGME's Next Accreditation System (NAS) Milestone performance tracking and reporting requirement and consider Entrustable Professional Activities (EPAs) to measure learner performanc
Externí odkaz:
https://doaj.org/article/10fca245ab89480e9aa8480ab0449eb3
Autor:
Sailaja Kamaraju, Amy Fowler, Lubna N. Chaudhary, Mark Burkard, Thomas Giever, Robert N Hegeman, Michele Pipp-Dahm, Yee Chung Cheng, Carol Lange, Julie M. Jorns, Amy Stella, Nauman Siddiqui, Luke Zurbriggen, Saurabh Rajguru, Sergey Tarima, Deepika Sriram, Janet Retseck, Hallgeir Rui, Tarek Sahmoud, Kari B. Wisinski
Publikováno v:
Cancer Research. 83:OT2-01
Background Antiprogestins, including selective progesterone receptor (PgR) modulators (SPRMs) that act as PgR antagonists, are a promising class of therapeutics for overcoming endocrine resistance including in patients who develop activating estrogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdb5ae297d29a385c35e767bc9e3e973
https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-02
https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-02
Autor:
Yanwen Jiang, Stephan Stilgenbauer, Mehrdad Mobasher, Gilles Salles, Barbara Eichhorst, William Schary, Michael Hallek, Franck Morschhauser, Daniela Soriano Pignataro, Huang Huang, Clemens-Martin Wendtner, Gerard Lozanski, Kathryn Humphrey, Guillaume Cartron, Thomas Giever, Mark Kozloff
Publikováno v:
Haematologica
Venetoclax (Ven), an orally administered, potent BCL-2 inhibitor, has demonstrated efficacy in chronic lymphocytic leukemia (CLL) in combination with rituximab (R) or obinutuzumab (G). Our aim was to investigate the addition of bendamustine (B) to th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fbd4b6167be804d13469413772f4ad6
http://europepmc.org/articles/PMC8561296
http://europepmc.org/articles/PMC8561296
Autor:
Petros Grivas, Behtash Ghazi Nezami, Thomas Giever, Gordon Goolamier, Matthew J. Riese, Adam Calaway, L. Ponsky, Emily Lemke, Kathryn A. Bylow, Deepak Kilari, John D. Burfeind, Mary Ann Draves, Ali Raza Khaki, Christopher J. Hoimes, Aniko Szabo, Leonidas Nikolaos Diamantopoulos, Samantha Rosey, Robert J. Cronk, Ariel Ann Nelson, Gregory T. MacLennan
Publikováno v:
Journal of Clinical Oncology. 38:e17007-e17007
e17007 Background: Outcomes of patients (pts) with mUC with EOM have not thoroughly been described in the age of immuno-oncology. We hypothesized that EOM is associated with worse outcomes when compared to pts with non-osseous metastases (NOM). Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f609be9c7cfd0e6d5c0640feb3c3ccc4
https://doi.org/10.1200/jco.2020.38.15_suppl.e17007
https://doi.org/10.1200/jco.2020.38.15_suppl.e17007
Autor:
Robert Peter Gale, Armand Keating, Andrea Bacigalupo, Hillard M. Lazarus, Reinhold Munker, Syed Ali Abutalib, Thomas Giever, Parameswaran Hari, Kerry Atkinson
Publikováno v:
Hematopoietic Cell Transplants: Concepts, Controversies, and Future Directions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c357438eb92dc32362125bdbcb9cd60
https://doi.org/10.1017/9781316335727.049
https://doi.org/10.1017/9781316335727.049
Autor:
Stephan Stilgenbauer, Mehrdad Mobasher, Michael Hallek, Gilles Salles, Gerard Lozanski, Daniela Soriano Pignataro, Clemens-Martin Wendtner, Mark Kozloff, Guillaume Cartron, Thomas Giever, William Schary, Kathryn Humphrey, Yanwen Jiang, Franck Morschhauser, Huang Huang, Barbara Eichhorst
Publikováno v:
Blood. 132:1859-1859
Introduction Anti-apoptotic protein BCL2 is overexpressed in hematologic malignancies such as CLL. BCL2 inhibitor VEN has shown profound efficacy when combined with B and anti-CD20 antibodies G and R, all of which are established components of CLL th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d7861b2ef20e0209bf1257c7c3dbf50
https://doi.org/10.1182/blood-2018-99-118362
https://doi.org/10.1182/blood-2018-99-118362
Publikováno v:
Journal of gastrointestinal and liver diseases : JGLD. 17(3)
We describe a 64-year-old man with squamous cell carcinoma of the esophagus who presented with an obstruction of the esophagus following radiation therapy and chemotherapy. Initial upper gastrointestinal barium swallow studies showed a complete stopp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::50ccb6f5a42f2ffc30a4c567b6294a48
https://pubmed.ncbi.nlm.nih.gov/18836631
https://pubmed.ncbi.nlm.nih.gov/18836631
Autor:
Paul S. Ritch, Arjun Ranade, James P. Thomas, Abdul H. Khan, Thomas Giever, Young S. Oh, Mario Gasparri, David W. Johnstone, Candice Johnstone, George B. Haasler, Ben George, Elizabeth Gore, Kulwinder S. Dua
Publikováno v:
Journal of Clinical Oncology. 33:54-54
54 Background: Definitive treatment for localized EC involves surgery alone or tri-modality therapy (TMT-chemotherapy, radiation, and surgery). TMT is administered to pts with clinical T2 or higher and lymph node (LN) positive ECs. Standard staging i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03bf530cddafe11bd947cf3b49826f14
https://doi.org/10.1200/jco.2015.33.3_suppl.54
https://doi.org/10.1200/jco.2015.33.3_suppl.54
Autor:
Thomas Giever, David W. Johnstone, Paul S. Ritch, Candice Johnstone, Mario Gasparri, George B. Haasler, Lauren A. Wiebe, Ben George, Elizabeth Gore, James P. Thomas
Publikováno v:
Cancer Research. 74:813-813
Introduction: Median survival associated with mEC is 9-12 months. While systemic therapy is the mainstay of treatment for mEC, there is no consensus regarding the best frontline chemotherapy combination. We evaluated the efficacy of CIP (Cisplatin 30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::559983bdf9dd17a2d51c7cf90105113d
https://doi.org/10.1158/1538-7445.am2014-813
https://doi.org/10.1158/1538-7445.am2014-813